Primary Vulvar Sarcoma in an Adolescent Li Freumani Patient

Dan G1, Yael R1 and Stella B2

1Tel Aviv Sourasky Medical Center, Division of Gynecologic Oncology, Affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel
2Tel Aviv Sourasky Medical Center, Institute of Pathology, Affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel

Corresponding author: Dan G, Tel Aviv Sourasky Medical Center, Division of Gynecologic Oncology, Affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Israel, Tel: 972-3-9625622; Fax: 972-3-9625670; E-mail: grisaro@post.tau.ac.il

Introduction

Originally described at 1969 [1], Li freumani syndrome (LFS) is an inherited autosomal dominant cancer predisposition syndrome associated with TP53 mutations. Also known as the Sarcoma, Breast, Leukemia and Adrenal Gland (SBLA) cancer syndrome, it is manifested by a range of malignancies occurring at an unusual early age. In addition to the "core malignancies" after which it was named, other tumors have been reported less frequently, including melanoma, gastric cancer, lymphoma, Wilms tumor and colorectal carcinoma [2-4]. The female lifetime risk for tumor development is approximately 100% depending on mutation type [5,6] and for both sexes, once a first tumor is diagnosed, the probability of developing a second malignancy within the following 30 years is very high -57%. Sarcomas account for approximately 25% of tumors in patients with TP53 germline mutations with median age of onset at 15 years [7,8].

Case

Our 15 years old female LFS patient first presented with right temporomandular rhabdiosarcoma with lung metastases treated with surgery and chemoradiation when she was only 3 y.o. At the age of 11 she was diagnosed with osteogenic sarcoma involving the left TMJ that has metastasized to the lungs. Notably, using the Chompret criteria, multiple tumors, two of which belong to the LFS tumor spectrum and the first of which occurred before age 46 years are sufficient for the diagnosis [9]. Despite adjuvant chemotherapy, 4 years later a tumor reappeared adjacent to the mandibular stump obligating resection and reconstruction of parts of the left maxilla, zygoma and orbit. At 13, osteogenic sarcoma of the left fibula was surgically removed with neoadjuvant chemotherapy, but a year later, when it reoccurred, a below knee amputation was necessary. She first presented to our Gyneco-oncologic unit with a right labial mass, Biopsy indicated sarcoma. Despite her age, considering the harmful effect of radiation, we recommended and performed partial right hemi vulvectomy (Figure 1A). Final pathological report confirmed the diagnosis of low grade sarcoma and free surgical margins (Figure 1B).

Discussion

Vulvar sarcomas are highly uncommon and account for 1.5-5% of all vulvar neoplasia [10,11]. Vulvar sarcomas in adolescent are even more rare, described only as several case reports [12,13]. To our knowledge, this is the first case of primary vulvar sarcoma in a LFS patient. This female is the only LFS patient out of 6 siblings. Being that this syndrome has a 100% penetrance, she probably carries a de novo mutation. As mentioned above, at 11 years of age, she was diagnosed with osteogenic sarcoma involving the left TMJ. This could be accounted, perhaps, to the radiation treatment she underwent. Accumulating data suggests that radiation induced cancers are more common in LFS [14,15] including one study in which half of the secondary sarcomas occurred in the radiation field [16]. It is now accepted that radiation should be avoided whenever possible.

Conclusion

The natural embarrassment delaying disclosure of genital findings at puberty and the importance of early diagnosis in sparing both mutilating surgery and hazardous radiation therapy obligates special attention by all caregivers.
References


